Tymlos is not a bisphosphonate. It belongs to a completely different class of osteoporosis drugs called osteoanabolic agents, which work by building new bone rather than slowing bone loss. The distinction matters because these two drug classes do fundamentally different things inside your skeleton, and they’re often used together in sequence as part of a long-term treatment plan.
How Tymlos Works Differently From Bisphosphonates
Bisphosphonates treat osteoporosis by putting the brakes on bone breakdown. They reduce the activity of osteoclasts, the cells that dissolve old bone tissue during the normal remodeling cycle. This slows bone loss, but it also slows bone formation as a side effect, since the two processes are linked. The net result is that you keep more of the bone you already have, but you don’t gain much new bone.
Tymlos (abaloparatide) takes the opposite approach. It’s a parathyroid hormone (PTH) receptor agonist, meaning it mimics a natural hormone that signals your body to ramp up bone-building activity. It stimulates osteoblasts, the cells responsible for laying down fresh bone. This produces real gains in bone density and strength rather than simply preserving what’s there. The three osteoanabolic drugs currently available are Tymlos, teriparatide (Forteo), and romosozumab (Evenity). All three actively stimulate bone formation, which bisphosphonates cannot do.
Who Tymlos Is Approved For
The FDA has approved Tymlos for postmenopausal women with osteoporosis who are at high risk for fracture, and for men with osteoporosis at high risk for fracture. “High risk” generally means you’ve already had an osteoporotic fracture, you have multiple risk factors, or you’ve tried other osteoporosis treatments that didn’t work or caused problems you couldn’t tolerate.
How You Take It
Tymlos is a daily injection you give yourself at home. The dose is 80 micrograms injected just under the skin in the lower abdomen, avoiding the two-inch area around your belly button. You rotate the injection site each day and try to inject at roughly the same time. The pen comes pre-filled and needs to be kept in the refrigerator (36°F to 46°F) before you start using it. Once you open it, you store it at room temperature and throw it away after 30 days, even if medicine remains inside.
The Two-Year Lifetime Limit
Tymlos is not a medication you stay on indefinitely. The FDA recommends no more than two years of use during your entire lifetime. This limit exists because in animal studies, abaloparatide caused a dose-dependent increase in osteosarcoma (a type of bone cancer) in rats at exposures 4 to 28 times the human dose. Whether this translates to humans is unknown. Observational studies in people have not shown an increased risk, but the data beyond two years of use is limited. The current FDA label addresses this in its warnings section rather than as a boxed warning.
If you experience new or persistent bone pain, unusual lumps, or swelling under the skin that’s tender to touch while on Tymlos, those are symptoms worth reporting to your provider promptly.
How Effective It Is at Preventing Fractures
In the ACTIVExtend trial, patients who took Tymlos for up to two years followed by the bisphosphonate alendronate saw an 84% relative reduction in vertebral fracture risk compared to those who received placebo followed by alendronate. Nonvertebral fractures dropped by 39%, clinical fractures by 34%, and major osteoporotic fractures by 50%. These are substantial reductions, particularly for vertebral fractures, which are the most common type of osteoporotic break.
Why Bisphosphonates Often Follow Tymlos
Here’s where the relationship between Tymlos and bisphosphonates gets practical. When you stop taking an anabolic drug like Tymlos, the bone gains you made start to reverse. The new bone your body built begins to break down again without ongoing protection. This is why follow-up treatment with an antiresorptive drug, typically a bisphosphonate or denosumab, is considered essential after finishing Tymlos. The antiresorptive locks in the bone density you gained during the anabolic phase.
Research consistently shows that starting with a bone-building agent and then switching to an antiresorptive produces substantially larger improvements in bone density than the reverse order. In one study, patients who stopped a PTH-based therapy and switched to placebo instead of an antiresorptive lost 2.7% of the bone density they had gained at the spine within a year. Patients who transitioned to an antiresorptive maintained their gains. So while Tymlos and bisphosphonates are different drug classes, they work best as partners in a planned sequence: build first, then protect.
Tymlos vs. Bisphosphonates at a Glance
- Drug class: Tymlos is an osteoanabolic (bone-building) agent. Bisphosphonates are antiresorptive (bone-preserving) agents.
- How they work: Tymlos stimulates cells that form new bone. Bisphosphonates suppress cells that break down existing bone.
- Administration: Tymlos is a daily self-injection. Most bisphosphonates are oral pills taken weekly or monthly, though some are given as yearly infusions.
- Duration: Tymlos has a two-year lifetime cap. Bisphosphonates can be used for years, though periodic reassessment is standard.
- Typical role: Tymlos is used first in high-risk patients to build bone quickly. Bisphosphonates often follow to maintain those gains long term.